Enterprise AI Strategy#

Conceptual Explanation#

Enterprise AI strategy operates at three levels that must be aligned for sustained value creation.

Level 1 — Use Case Strategy: Which problems should AI solve? Not all problems that AI can solve are worth solving. Use case prioritization requires estimating business impact, technical feasibility, data availability, regulatory risk, and time to value. Organizations that skip this discipline pursue the AI use cases that are easiest to demonstrate rather than those that generate the most value.

Level 2 — Platform Strategy: How should the organization's AI capabilities be structured? Should each team build its own AI stack, or should a shared platform provide common services — inference, embeddings, vector storage, evaluation, observability — to all teams? Platform strategy determines the long-term cost structure and capability velocity of the AI program.

Level 3 — Organizational Strategy: How does the organization need to change to capture AI value? AI systems do not deliver value in isolation — they change workflows, shift responsibilities, and require new skills. Organizations that treat AI as a technology problem rather than an organizational change problem routinely underutilize their AI investments.

The three levels interact: a use case strategy that ignores platform realities produces duplicated infrastructure; a platform strategy that ignores organizational readiness produces tools that no one uses; an organizational strategy that ignores use case ROI produces training programs without outcomes.

Core Architecture#

The AI strategy development process follows a structured sequence:

Step 1 — Landscape Assessment: Catalog the current state of AI adoption across the organization. Identify shadow AI (tools already in use without governance), existing AI investments, data assets, and engineering capacity. This prevents strategy from being disconnected from organizational reality.

Step 2 — Use Case Discovery: Generate a candidate list of AI use cases through structured workshops with business and clinical stakeholders. Use the "pain point first, AI second" approach: identify the most expensive operational problems before asking how AI might address them.

Step 3 — Portfolio Scoring: Score each candidate use case on two dimensions — business impact (revenue, cost, quality, risk) and feasibility (data availability, technical complexity, regulatory risk, integration complexity). Plot the portfolio on a 2x2 matrix to identify quick wins, strategic bets, and initiatives to deprioritize.

Step 4 — Build-Buy-Partner Decision: For each prioritized use case, determine whether to build a custom solution, buy a commercial AI product, or partner with a vendor to co-develop. This decision is governed by differentiation (is the AI capability a source of competitive advantage?), time to value (how quickly must the solution be operational?), and capability (does the organization have the engineering capacity to build and maintain it?).

Step 5 — TCO Modeling: Calculate the true cost of each approach over a 3-year horizon. Build costs include engineering, infrastructure, data preparation, evaluation, and ongoing operations. Buy costs include licensing, integration, customization, and vendor dependency. Partner costs are hybrid.

Step 6 — Roadmap Construction: Sequence the portfolio into a 12–18 month roadmap with explicit dependencies, resource allocations, and success metrics defined before work begins.

Architecture Diagram#

Common Mistakes#

Pursuing the Impressive Rather Than the Valuable. The AI use cases that generate the best board room demos — generative agents, multimodal analysis, autonomous workflows — are often the least mature and most risky to deploy. The use cases that generate the most durable value — document classification, structured data extraction, semantic search, content summarization — are rarely impressive to demonstrate but reliably reduce operating costs at scale.

Treating AI Strategy as an IT Roadmap. AI strategy is a business strategy that has technical implications. Organizations that house AI strategy entirely within IT produce technology plans without business ownership, which fail to secure funding, fail to navigate clinical and operational change, and fail to demonstrate ROI in business terms.

Underestimating the Operational Tail. The cost to build an AI system is typically 30–40% of the total cost of owning it over three years. Evaluation infrastructure, ongoing monitoring, prompt iteration as models are updated, and clinical validation for healthcare AI are ongoing operational costs that must be budgeted in year one.

Starting With the Platform. Organizations that invest in AI platform infrastructure before validating use cases often build platforms that are poorly matched to actual requirements. The correct sequence is: validate 2–3 use cases with direct API integrations first, then extract the shared patterns into a platform.

Best Practices#

• Begin every AI initiative with a quantified business case: specific problem, specific metric, specific target value, specific timeline
• Run use case discovery with clinical and operational stakeholders, not with the AI team proposing solutions
• Define "done" for each AI investment before starting: what metric, measured how, at what threshold, declares success
• Maintain a single source of truth for the AI portfolio that is reviewed quarterly by leadership
• Require a BAA and data flow assessment before any PHI touches an external AI system
• Plan for regulatory classification at the start of any clinical decision support use case, not after development is complete
• Budget 20% of the AI program budget for evaluation, observability, and governance infrastructure

Alternatives#

Center of Excellence (CoE) Model. A central AI team owns all AI development and serves internal business units as clients. Advantages: consistent standards, shared expertise, no duplication. Disadvantages: creates a bottleneck, may be too removed from clinical workflow realities to build effective clinical AI. Best suited for organizations in early AI maturity.

Federated Team Model. Each business unit has embedded AI engineers supported by central platform services and governance. Advantages: faster iteration, closer to the problem domain. Disadvantages: requires more total headcount, governance is harder to enforce. Best suited for organizations with multiple distinct AI domains (clinical, administrative, research).

Platform Team Model. A central platform team builds shared AI infrastructure; business units build their own applications on top. This model scales best in large organizations with multiple high-velocity AI teams.

Trade-offs#

Interview Questions#

Q: How do you structure an AI strategy for a healthcare organization that has never deployed production AI before?#

Category: System Design Difficulty: Principal Role: AI Architect / FDE

Answer Framework:

Start with an organizational readiness assessment before any technology discussion. Evaluate data maturity (is the EHR data accessible, clean, and labeled?), engineering capacity (are there AI engineers on staff or is this a consulting engagement?), governance (does the organization have a legal and compliance process for AI review?), and clinical leadership engagement (is there a physician champion willing to validate and defend AI outputs?).

Then run a structured discovery process to identify the 3–5 highest-value problems that AI can solve with available data and acceptable regulatory risk. Resist the temptation to solve the most complex problems first. Early wins — ambient documentation, structured data extraction, search improvement — build credibility and generate the organizational learning needed to tackle harder problems.

Define the build-buy-partner framework explicitly. For a first-time AI deployer, the recommendation is almost always to buy for commodity capabilities and build only where the clinical workflow integration is so specific that no vendor solution will fit.

Key Points to Hit:

• Organization readiness before technology selection
• Problem-first, AI-second discovery process
• Build-buy-partner decision based on differentiation, not technical preference
• Clinical validation requirements as a planning input, not an afterthought
• Define success metrics before development starts

Follow-up Questions:

• How do you handle a situation where the clinical champion and the compliance team have conflicting requirements?
• How do you build the business case for AI infrastructure investment before the first use case has proven value?

Red Flags (What NOT to say):

• Starting with model selection or vendor comparison before understanding the problem
• Ignoring regulatory considerations as "something legal handles"
• Treating AI governance as an overhead rather than a strategic enabler

Q: A hospital CIO asks you to evaluate whether to build a custom prior authorization AI system or buy a vendor solution. Walk me through your evaluation framework.#

Category: Architecture Difficulty: Senior Role: AI Architect / FDE

Answer Framework:

Structure the evaluation around four dimensions: differentiation, capability, time to value, and total cost of ownership.

Differentiation: Prior authorization is operationally critical but not clinically differentiated — the hospital does not gain competitive advantage by having a uniquely superior prior auth system. This is an initial signal toward buying.

Capability: Does the vendor solution support the hospital's specific payer mix, EHR system (likely Epic), and clinical workflow requirements? Vendor solutions often cover 70–80% of use cases well but require workarounds for the remaining 20%. Quantify what falls outside the vendor's coverage.

Time to value: Prior authorization automation has a 6-month implementation timeline for a commercial solution versus an 18-month timeline to build. The business value of 12 additional months of operation at the commercial solution's estimated ROI may exceed the long-term cost difference.

TCO: Model the full 3-year cost including licensing, integration, configuration, ongoing support, and customization versus the build cost including engineering headcount, infrastructure, evaluation, compliance, and maintenance. Build costs are routinely underestimated by 30–50% in first-pass estimates.

The likely recommendation for most hospitals: buy a commercial solution, negotiate API access for tight EHR integration, and use the time saved to focus engineering capacity on more differentiating clinical AI use cases.

Key Points to Hit:

• Differentiation is the primary driver; prior auth is not differentiating
• TCO must include operational costs, not just build costs
• Time-to-value opportunity cost is often decisive
• Quantify the gap between vendor coverage and clinical requirements before deciding

Red Flags:

• Recommending build because "we'll have more control"
• Ignoring the 3-year cost model
• Not evaluating vendor solution capabilities before making the recommendation

Q: How do you prevent an enterprise AI program from becoming a collection of disconnected pilots that never reach production?#

Category: Architecture / Behavioral Difficulty: Principal Role: AI Architect / Engineering Manager

Answer Framework:

The pilot-to-nowhere pattern has three structural causes: misaligned success criteria (the pilot is designed to demonstrate technical feasibility, not business value), absent governance (there is no defined process for moving from pilot to production), and disconnected business ownership (engineering built the pilot, but the business unit that would operate it was not engaged in its design).

The structural fix is a portfolio process that treats every AI initiative as a managed investment from day one. Define the business case quantitatively before starting. Assign a business owner who is accountable for the value case — not just an engineering sponsor. Define the production criteria explicitly: what metric must the system achieve in the pilot to justify production deployment? If the pilot fails to meet those criteria, it is terminated, not extended indefinitely.

At the governance level, require that every pilot has an approved production plan before it begins. This forces the organization to think through integration, compliance, operational support, and change management before building, not after.

Key Points to Hit:

• Pilots fail at production because production requirements were never designed into them
• Business ownership (not engineering ownership) is the prerequisite for production success
• Define exit criteria before starting, not after the pilot has accumulated sunk costs
• Governance at the portfolio level prevents the accumulation of stranded pilots

Red Flags:

• Attributing pilot-to-nowhere to technical failures (it is almost always organizational)
• Proposing to fix it by building better demos
• Ignoring the role of business change management in production deployment

Key Takeaways#

• Enterprise AI strategy operates at three levels: use case, platform, and organizational — all three must be aligned
• Use case prioritization on impact and feasibility is more valuable than any technical capability assessment
• The build-versus-buy decision is governed by differentiation, capability, time to value, and total cost of ownership — not by technical preference
• Healthcare AI strategy requires regulatory classification as a first-order planning input, not a downstream concern
• The total cost of owning an AI system over three years is typically 2.5–3.5× the cost to build it
• Pilots that do not define production criteria before starting are structurally incapable of reaching production
• An AI steering committee with cross-functional authority is prerequisite to sustained AI program success